Chemotherapy and hormone therapy for uterine sarcomas

Hiroshi Yamashita, Hiroharu Arai, Daisuke Aoki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Uterine sarcomas are relatively rare mesenchymal malignant neoplasms with poor prognosis, accounting for 8% of all uterine malignant neoplasms. There are only a few moderately active cytotoxic agents for this entity, and therefore, chemotherapy for uterine sarcomas is palliative in most cases. According to traditional classification systems, uterine sarcomas encompass carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal cell sarcoma (ESS). For carcinosarcoma, ifosfamide, cisplatin, and paclitaxel are reported to be moderately effective single agents. The combination of ifosfamide and cisplatin appeared to improve progression-free survival, but the severe toxicity it induced was not negligible. Paclitaxel and ifosfamide were the only chemotherapy regimen which slightly improved both progression-free and overall survival. For leiomyosarcoma and undifferentiated endometrial sarcoma (formerly named high-grade ESS), doxorubicin, ifosfamide, and gemcitabine are moderately effective single agents. There are several reports showing the effectiveness of gemcitabine plus docetaxel. For endometrial stromal sarcoma (formerly named low-grade ESS), progestins and aromatase inhibitors have been proven beneficial.

Original languageEnglish
Pages (from-to)722-725
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number5
Publication statusPublished - 2012 May

Fingerprint

Ifosfamide
Endometrial Stromal Sarcoma
gemcitabine
Sarcoma
Stromal Cells
Hormones
Carcinosarcoma
Drug Therapy
Leiomyosarcoma
docetaxel
Disease-Free Survival
Endometrial Stromal Tumors
Uterine Neoplasms
Aromatase Inhibitors
Cytotoxins
Progestins
Therapeutics
Paclitaxel
Doxorubicin
Cisplatin

Keywords

  • Carcinosarcoma
  • Chemotherapy
  • Endometrial stromal sarcoma
  • Leiomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy and hormone therapy for uterine sarcomas. / Yamashita, Hiroshi; Arai, Hiroharu; Aoki, Daisuke.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 5, 05.2012, p. 722-725.

Research output: Contribution to journalArticle

Yamashita, Hiroshi ; Arai, Hiroharu ; Aoki, Daisuke. / Chemotherapy and hormone therapy for uterine sarcomas. In: Japanese Journal of Cancer and Chemotherapy. 2012 ; Vol. 39, No. 5. pp. 722-725.
@article{92da9d5e0dce45e3b3f4a68986b5dc37,
title = "Chemotherapy and hormone therapy for uterine sarcomas",
abstract = "Uterine sarcomas are relatively rare mesenchymal malignant neoplasms with poor prognosis, accounting for 8{\%} of all uterine malignant neoplasms. There are only a few moderately active cytotoxic agents for this entity, and therefore, chemotherapy for uterine sarcomas is palliative in most cases. According to traditional classification systems, uterine sarcomas encompass carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal cell sarcoma (ESS). For carcinosarcoma, ifosfamide, cisplatin, and paclitaxel are reported to be moderately effective single agents. The combination of ifosfamide and cisplatin appeared to improve progression-free survival, but the severe toxicity it induced was not negligible. Paclitaxel and ifosfamide were the only chemotherapy regimen which slightly improved both progression-free and overall survival. For leiomyosarcoma and undifferentiated endometrial sarcoma (formerly named high-grade ESS), doxorubicin, ifosfamide, and gemcitabine are moderately effective single agents. There are several reports showing the effectiveness of gemcitabine plus docetaxel. For endometrial stromal sarcoma (formerly named low-grade ESS), progestins and aromatase inhibitors have been proven beneficial.",
keywords = "Carcinosarcoma, Chemotherapy, Endometrial stromal sarcoma, Leiomyosarcoma",
author = "Hiroshi Yamashita and Hiroharu Arai and Daisuke Aoki",
year = "2012",
month = "5",
language = "English",
volume = "39",
pages = "722--725",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Chemotherapy and hormone therapy for uterine sarcomas

AU - Yamashita, Hiroshi

AU - Arai, Hiroharu

AU - Aoki, Daisuke

PY - 2012/5

Y1 - 2012/5

N2 - Uterine sarcomas are relatively rare mesenchymal malignant neoplasms with poor prognosis, accounting for 8% of all uterine malignant neoplasms. There are only a few moderately active cytotoxic agents for this entity, and therefore, chemotherapy for uterine sarcomas is palliative in most cases. According to traditional classification systems, uterine sarcomas encompass carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal cell sarcoma (ESS). For carcinosarcoma, ifosfamide, cisplatin, and paclitaxel are reported to be moderately effective single agents. The combination of ifosfamide and cisplatin appeared to improve progression-free survival, but the severe toxicity it induced was not negligible. Paclitaxel and ifosfamide were the only chemotherapy regimen which slightly improved both progression-free and overall survival. For leiomyosarcoma and undifferentiated endometrial sarcoma (formerly named high-grade ESS), doxorubicin, ifosfamide, and gemcitabine are moderately effective single agents. There are several reports showing the effectiveness of gemcitabine plus docetaxel. For endometrial stromal sarcoma (formerly named low-grade ESS), progestins and aromatase inhibitors have been proven beneficial.

AB - Uterine sarcomas are relatively rare mesenchymal malignant neoplasms with poor prognosis, accounting for 8% of all uterine malignant neoplasms. There are only a few moderately active cytotoxic agents for this entity, and therefore, chemotherapy for uterine sarcomas is palliative in most cases. According to traditional classification systems, uterine sarcomas encompass carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal cell sarcoma (ESS). For carcinosarcoma, ifosfamide, cisplatin, and paclitaxel are reported to be moderately effective single agents. The combination of ifosfamide and cisplatin appeared to improve progression-free survival, but the severe toxicity it induced was not negligible. Paclitaxel and ifosfamide were the only chemotherapy regimen which slightly improved both progression-free and overall survival. For leiomyosarcoma and undifferentiated endometrial sarcoma (formerly named high-grade ESS), doxorubicin, ifosfamide, and gemcitabine are moderately effective single agents. There are several reports showing the effectiveness of gemcitabine plus docetaxel. For endometrial stromal sarcoma (formerly named low-grade ESS), progestins and aromatase inhibitors have been proven beneficial.

KW - Carcinosarcoma

KW - Chemotherapy

KW - Endometrial stromal sarcoma

KW - Leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84864024657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864024657&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 722

EP - 725

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -